Analystreport

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $7.00 price target on the stock.

Rigel Pharmaceuticals, Inc.  (RIGL) 
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.rigel.com